Retatrutide Phase 3 Data Is In — Now Comes the Hard Part

Retatrutide phase 3 manufacturing capacity and supply chain bottlenecks in 2026

Retatrutide Phase 3 has delivered its first pivotal result, and the efficacy numbers are not in doubt. What happens next — manufacturing at scale and persuading payers to cover it — will determine whether those numbers translate into actual patient access, or whether Lilly repeats the Mounjaro supply bottleneck at a higher order of complexity. … Read more

The GLP-1 Manufacturing Race Is a Supply Chain Problem, Not a Drug Problem

GLP-1 manufacturing sterile injectable fill-finish facility and supply capacity

GLP-1 manufacturing is becoming the bottleneck that decides who can supply the next wave of obesity drugs, and capital is following the capacity. Eli Lilly committed $6B to a single manufacturing plant in Huntsville, Alabama, in December 2025 — the largest single-site pharmaceutical investment in state history. Amgen followed in April 2026 with a $900M … Read more